Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK146D1 Monotherapy or Combined With AK112 in Advanced Urothelial Carcinoma
NCT07636772Phase 2Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jun 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of AK146D1 in urothelial carcinoma (UC), sponsored by Akeso, Inc.. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
AK146D1
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07636772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07636772.